# A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

> **NCT00386152** · PHASE2 · TERMINATED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 235 (actual)

## Conditions studied

- Neoplasms
- Anemia
- Cancer

## Interventions

- **DRUG:** epoetin alfa
- **DRUG:** darbepoetin alfa

## Key facts

- **NCT ID:** NCT00386152
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11
- **Primary completion:** 2008-03
- **Final completion:** 2008-05
- **Target enrollment:** 235 (ACTUAL)
- **Why stopped:** No safety signals were noted. The study was stopped because it was no longer consistent with the company's scientific and strategic focus.
- **Last updated:** 2013-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00386152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00386152, "A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00386152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*